3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Genitourinary
2
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
CNS
1
Conditions
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
41
Nivolumab
18
atezolizumab
8
Specimen Handling
7
Docetaxel
7
durvalumab
6
Paclitaxel
6
Magnetic Resonance Spectroscopy
6
Ipilimumab
6
Cyclophosphamide
6
Carboplatin
6
fludarabine
4
avelumab
4
Oxaliplatin
4
Leucovorin
4
Early Intervention, Educational
4
Counseling
4
Biopsy
4
temsirolimus
3
spartalizumab
3
pazopanib
3
olaparib
3
lenvatinib
3
cabozantinib
3
aldesleukin
3
Trastuzumab
3
Taxes
3
Sirolimus
3
Psychiatric Rehabilitation
3
Fluorouracil
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
cabiralizumab
×
Gynecologic
×
Clear all
NCT02526017
2022-03-09
FPA008-003
Five Prime Therapeutics, Inc.
Phase 1
Completed
313 enrolled
30 charts